

## Agreement 2: Oncology Risk-Share Model

Parties: OncoTherapeutics Ltd. and Universal Health Partners Country: United Kingdom Disease Area: Metastatic Colorectal Cancer Agreement Overview: This pioneering agreement addresses the high cost and uncertain outcomes associated with advanced cancer treatments. Focusing on third-line therapy for metastatic colorectal cancer patients who have failed standard treatments, this contract creates a balanced risk-sharing model between manufacturer and payer. The agreement covers approximately 285 patients annually across 14 treatment centers in the UK and was established following NICE conditional recommendation requiring real-world evidence generation.

### Financial Structure:

- Upfront treatment cost: £85,000 per patient for complete treatment course
- Money-back guarantee: 80% refund (£68,000) if no response within 90 days as determined by RECIST 1.1 criteria
- Success payments:
  - 25% premium (£21,250) if progression-free survival exceeds 12 months (vs. historical median of 5.2 months)
  - Stepped payment model: £15,000 for each 3-month survival milestone beyond median, payable quarterly
- Cost-sharing: Payer covers 50% of costs for adverse event management exceeding Grade 3 toxicity (capped at £10,000 per patient)
- Annual spending cap: £7.5 million across patient population with excess costs fully absorbed by manufacturer
- Performance tracking: Independent oncology data registry with quarterly assessment and reconciliation
- Patient-reported outcome component: £2,500 bonus per patient reporting stable/improved quality of life for 6+ months

### Duration: 5 years with midpoint comprehensive evaluation Special Provisions:

- Includes genetic testing costs for biomarker identification and therapy selection (£3,200 per patient)
- Personalized dosing protocols based on pharmacogenomic profiling
- Compassionate access program for patients exceeding normal eligibility criteria
- Comprehensive patient support program including dedicated nurse navigators
- Real-world evidence generation protocol with academic partnership for publication
- Knowledge transfer program to UK oncology centers for optimizing treatment protocols